Research programme: fixed combination respiratory tract disorder therapeutics - NIOX
Alternative Names: PSX 2000 MCP Series; PSX 3000 MCPTM Series; PSX MCP™ SeriesLatest Information Update: 21 Mar 2023
At a glance
- Originator Prosonix
- Developer Imperial College of Science, Technology and Medicine; NIOX
- Class Androstadienes; Antiasthmatics; Ethanolamines; Phenethylamines; Pregnenediones; Small molecules
- Mechanism of Action Arachidonic acid inhibitors; Beta 2 adrenergic receptor agonists; Glucocorticoid receptor agonists; Lipocortin synthesis agonists; Steroid receptor agonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- Discontinued Asthma; Chronic obstructive pulmonary disease; Respiratory tract disorders
Most Recent Events
- 21 Mar 2023 Discontinued - Preclinical for Asthma in United Kingdom (Inhalation)
- 21 Mar 2023 Discontinued - Preclinical for Chronic obstructive pulmonary disease in United Kingdom (Inhalation)
- 21 Mar 2023 Discontinued - Preclinical for Respiratory tract disorders in United Kingdom (Inhalation)